Kurtoglu Metin has filed 43 insider transactions across 1 company since November 2023.
Most recent transaction: a sale of 2417 shares of Cartesian Therapeutics, Inc. ($RNAC) on January 03, 2025.
Activity breakdown: 0 open-market purchases and 14 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 3, 2025 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 2417 | $16.72 | 64,716.0000 | 25,767,369 | 3.60% | 0.01% |
| Jan. 6, 2025 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 2458 | $16.83 | 62,258.0000 | 25,767,369 | 3.80% | 0.01% |
| Jan. 2, 2025 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | A | Common Stock | 16100 | $0.00 | 67,133.0000 | 25,767,369 | 31.55% | 0.06% |
| Jan. 2, 2025 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | A | Employee Stock Option (right to buy) | 47400 | $0.00 | 47,400.0000 | 25,767,369 | 9999.99% | 0.18% |
| Dec. 9, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Common Stock | 10763 | $1.41 | 61,796.0000 | 23,896,525 | 21.09% | 0.05% |
| Dec. 9, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 6224 | $25.26 | 55,572.0000 | 23,896,525 | 10.07% | 0.03% |
| Dec. 9, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 4539 | $25.83 | 51,033.0000 | 23,896,525 | 8.17% | 0.02% |
| Dec. 10, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Common Stock | 2901 | $1.41 | 53,934.0000 | 23,896,525 | 5.68% | 0.01% |
| Dec. 10, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 2901 | $24.35 | 51,033.0000 | 23,896,525 | 5.38% | 0.01% |
| Dec. 9, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 10763 | $0.00 | 82,000.0000 | 23,896,525 | 11.60% | 0.05% |
| Dec. 10, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 2901 | $0.00 | 79,099.0000 | 23,896,525 | 3.54% | 0.01% |
| Nov. 19, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Common Stock | 200 | $1.41 | 51,233.0000 | 23,896,525 | 0.39% | 0.00% |
| Nov. 19, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 200 | $19.50 | 51,033.0000 | 23,896,525 | 0.39% | 0.00% |
| Nov. 20, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Common Stock | 5700 | $1.41 | 56,733.0000 | 23,896,525 | 11.17% | 0.02% |
| Nov. 20, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 5600 | $17.28 | 51,133.0000 | 23,896,525 | 9.87% | 0.02% |
| Nov. 20, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 100 | $18.09 | 51,033.0000 | 23,896,525 | 0.20% | 0.00% |
| Nov. 21, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Common Stock | 32789 | $1.41 | 83,822.0000 | 23,896,525 | 64.25% | 0.14% |
| Nov. 21, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 32789 | $16.67 | 51,033.0000 | 23,896,525 | 39.12% | 0.14% |
| Nov. 19, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 200 | $0.00 | 131,252.0000 | 23,896,525 | 0.15% | 0.00% |
| Nov. 20, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 5700 | $0.00 | 125,552.0000 | 23,896,525 | 4.34% | 0.02% |
| Nov. 21, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 32789 | $0.00 | 92,763.0000 | 23,896,525 | 26.12% | 0.14% |
| Nov. 14, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Common Stock | 25900 | $1.41 | 76,933.0000 | 23,896,525 | 50.75% | 0.11% |
| Nov. 14, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 21900 | $16.33 | 55,033.0000 | 23,896,525 | 28.47% | 0.09% |
| Nov. 14, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 4000 | $17.06 | 51,033.0000 | 23,896,525 | 7.27% | 0.02% |
| Nov. 15, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Common Stock | 22068 | $1.41 | 73,101.0000 | 23,896,525 | 43.24% | 0.09% |
| Nov. 15, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 22068 | $17.20 | 51,033.0000 | 23,896,525 | 30.19% | 0.09% |
| Nov. 18, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Common Stock | 34400 | $1.41 | 85,433.0000 | 23,896,525 | 67.41% | 0.14% |
| Nov. 18, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 16672 | $18.19 | 68,761.0000 | 23,896,525 | 19.51% | 0.07% |
| Nov. 18, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | S | Common Stock | 17728 | $18.58 | 51,033.0000 | 23,896,525 | 25.78% | 0.07% |
| Nov. 14, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 25900 | $0.00 | 187,920.0000 | 23,896,525 | 12.11% | 0.11% |
| Nov. 15, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 22068 | $0.00 | 165,852.0000 | 23,896,525 | 11.74% | 0.09% |
| Nov. 18, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 34400 | $0.00 | 131,452.0000 | 23,896,525 | 20.74% | 0.14% |
| April 8, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 6415 | $0.00 | 65,499.0000 | 5,515,836 | 8.92% | 0.12% |
| April 8, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 213820 | $0.00 | 279,319.0000 | 5,515,836 | 326.45% | 3.88% |
| April 8, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 428 | $0.00 | 65,499.0000 | 5,515,836 | 0.65% | 0.01% |
| April 8, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 14254 | $0.00 | 79,753.0000 | 5,515,836 | 21.76% | 0.26% |
| April 8, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 428 | $0.00 | 65,499.0000 | 5,515,836 | 0.65% | 0.01% |
| April 8, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Technology Officer | M | Stock Option (Right to Buy) | 14254 | $0.00 | 79,753.0000 | 5,515,836 | 21.76% | 0.26% |
| Jan. 2, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Operating Officer | A | Common Stock | 1531000 | $0.00 | 1,531,000.0000 | 5,397,597 | 9999.99% | 28.36% |
| Jan. 2, 2024 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Operating Officer | A | Employee Stock Option (right to buy) | 1965000 | $0.00 | 1,965,000.0000 | 5,397,597 | 9999.99% | 36.41% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Operations Officer | A | Stock Option (Right to Buy) | 6415 | $0.00 | 6,414.6820 | 5,101,459 | 9999.99% | 0.13% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Operations Officer | A | Stock Option (Right to Buy) | 428 | $0.00 | 427.6450 | 5,101,459 | 9999.99% | 0.01% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | Kurtoglu Metin | Chief Operations Officer | A | Stock Option (Right to Buy) | 428 | $0.00 | 427.6450 | 5,101,459 | 9999.99% | 0.01% |